MHEALTH GOLDEN AGE MOBILE SECURITY IMPLICATIONS

Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a given patient. In order to expeditiously evaluate a targeted agent against a potential ‘driver’ genetic aberration, so-called Basket trials are conducted.

Pharmaceutical manufacturers are facing unprecedented challenges from supply chain disruptions, significant demand fluctuations, reliability.

Join this webinar to discover the advantages of using Signatura™ (RUO), a novel assay custom-designed for each patient that detects circulating tumour DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumours. Learn about the latest clinical data for Signatura and explore how this unique ctDNA assay can be applied in pharmaceutical development and oncology clinical study design, potentially increasing the probability of trial success, reduce the time to trial readout, and decrease clinical trial costs

The practitioner who wishes to get started in GDP orthodontics faces a bewildering array of choices: clear aligners or fixed appliances? Which product is best to get started with? How to overcome one’s poor foundation of orthodontic knowledge from undergraduate training, when much of the information learned for final exams has subsequently been forgotten? Since 2001, the Invisalign product has been used to treat over 5 million cases worldwide. This vast bank of clinical experience is constantly used to refine and improve the product, and also makes the Invisalign system the most streamlined experience for a new user who is improving their orthodontic skills and the safest place to re-start one’s journey in orthodontics.